Table 1.
Patient characteristics.
| Variable | Overall n = 169 (%) |
|---|---|
| Age | |
| Median (range) | 69 (33–85) |
| Gender | |
| Female | 76 (45%) |
| Male | 93 (55%) |
| Grading | |
| 1 | 14 (9%) |
| 2 | 53 (34%) |
| 3 | 59 (38%) |
| 4 | 30 (19%) |
| Unknown | 13 |
| ECOG PS | |
| 0 | 127 (75%) |
| 1 | 39 (23%) |
| 2 | 3 (2%) |
| Tumor localization | |
| Rectum | 32 (19%) |
| Right colon | 64 (39%) |
| Left colon | 69 (42%) |
| Unknown | 4 |
| Site of metastases | |
| Liver | 98 (58%) |
| Lung | 63 (37%) |
| Peritoneum | 40 (24%) |
| Metastases | |
| Sinchronous | 79 (52%) |
| Metachronous | 74 (48%) |
| Missing | 16 |
| Stage at diagnosis in metachronous group | |
| Stage I | 3 (5%) |
| Stage II | 14 (33%) |
| Stage III | 26 (60%) |
| Missing | 31 |
| Chemotherapy regimen | |
| FOLFOX | 107 (63%) |
| FOLFIRI | 41 (24%) |
| CAPOX | 12 (7%) |
| CAPIRI | 1 (1%) |
| Other | 8 (5%) |
| Previous surgery | |
| Yes | 124 (74%) |
| No | 44 (26%) |
| Unknown | 1 |
| Previous adjuvant chemotherapy | |
| Yes | 50 (30%) |
| No | 117 (70%) |
| Unknown | 2 |
| KRAS | |
| Wild type | 67 (42%) |
| Mutated | 93 (58%) |
| Unknown | 9 |
| NRAS | |
| Wild type | 141 (93%) |
| Mutated | 10 (7%) |
| Unknown | 18 |
| BRAF | |
| Wild type | 122 (87%) |
| Mutated | 19 (13%) |
| Unknown | 28 |
ECOG PS, Eastern Cooperative Oncology Group Performance Status.